GamaMabs Pharma Announces Two Scientific Communications on Its AMHR2 Project

Two studies on AMHR2 project were accepted for a publication in mAbs journal and a poster by Institut Curie (Paris, France) at the 10th Biennial Ovarian Cancer Research Symposium (Seattle, 8-9 September 2014)

TOULOUSE, France--()--GamaMabs Pharma, which holds exclusive rights on 12G4 and 3C23K monoclonal antibodies targeting AMHR2 / MISR2, announces two communications on these antibodies.

The article, “The human Müllerian inhibiting substance type 2 receptor as immunotherapy target for Ovarian Cancer: validation using the mAb 12G4”, N Kersual / I Navarro-Teulon, is published in mAbs (Vol. 6, Issue 5, 2014) by IRCM and ICM teams (France). The article shows that the 12G4 murine antibody targeting AMHR2 increases the survival of mice bearing ovarian tumor and confirms AMHR2 as a promising target for ovarian cancer treatment.

The second scientific communication is the poster “In vivo synergism between chemotherapy and the 3C23K monoclonal antibody directed against the anti-Müllerian hormone type 2 receptor in ovarian cancer patient derived xenografts” by F Nemati, Dr Didier Decaudin et al., from Institut Curie in collaboration with GamaMabs Pharma, and presented at the 10th Biennial Ovarian Cancer Research Symposium of Seattle on 8-9 of September 2014. It summarizes the study based on 14 Patient Derived Xenografts confirming AMHR2 expression in ovarian cancer, and describes 3C23K synergistic therapeutic effect in combination with standard chemotherapy.

Jean-François Prost, VP R&D and Strategy GamaMabs Pharma says « We are happy those communications from famous institutions validate the therapeutic interest of our humanized antibody 3C23K targeting AMHR2 in Gynaecologic cancers.»

About Institut Curie
Institut Curie is a private foundation granted charitable status, which combines the largest French oncology research center and two state-of-the-art hospitals. This hospital structure has pioneered many treatments. It is a center of excellence for the treatment of breast cancer, pediatric tumors and ocular tumors, and it disseminates medical and scientific innovations in France and abroad.
Founded in 1909 on a model devised by Marie Curie and still at the cutting edge: "from fundamental research to innovative treatments", Institut Curie has 3,400 researchers, physicians, clinicians, technicians and administrative staff.
For more information: www.curie.fr

About GamaMabs Pharma
GamaMabs Pharma is a French Biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K, currently in advanced pre-clinical stage, which targets Anti-Mullerian Human Receptor 2 (AMHR2 / MISR2) in ovarian cancer. Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States.The company values high-potential technologies in oncology developed initially at LFB Biotechnologies including EMABling® which increases mAbs’ activity through the activation of immune system cells.
www.gamamabs.com

Contacts

GamaMabs Pharma
Jean-François Prost
+33 1 70 96 00 68
VP R&D and strategy
jfprost@gamamabs.com

(Graphic: Institut Curie)

???news_view.multimedia.download???

???pagination.previous??? ???pagination.next???

Release Summary

GamaMabs Pharma announces two scientific communications on its AMHR2 project.

Sharing

Contacts

GamaMabs Pharma
Jean-François Prost
+33 1 70 96 00 68
VP R&D and strategy
jfprost@gamamabs.com